Celecoxib inhibits tumor growth and angiogenesis in an orthotopic implantation tumor model of human colon cancer

Experimental Oncology

Volumn 30, Issue 1, 2008, Pages 42-51

  Wang, L ^a   Chen, W ^a   Xie, X ^a   He, Y ^a   Bai, X ^a  

^a SOOCHOW UNIVERSITY   (China)

Author keywords

Angiogenesis; Colon cancer; Cyclooxygenase 2; Orthotopic implantation; Prostaglandin E2

Indexed keywords

CD34 ANTIGEN; CELECOXIB; CYCLOOXYGENASE 2; GELATINASE A; MESSENGER RNA; PROSTAGLANDIN E2; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BODY WEIGHT; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER MODEL; CANCER TRANSPLANTATION; CAPILLARY DENSITY; COLON ADENOCARCINOMA; COLORECTAL CARCINOMA; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EXPOSURE; DRUG MECHANISM; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NICK END LABELING; NONHUMAN; NUDE MOUSE; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; RADIOIMMUNOASSAY; RECTUM CARCINOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; TISSUE HOMOGENATE; TISSUE LEVEL; TUMOR VOLUME; WEIGHT;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; FEMALE; HT29 CELLS; HUMANS; MATRIX METALLOPROTEINASE 2; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PYRAZOLES; SULFONAMIDES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 42049088505     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10-30.
2. Brown JR, DuBois RN. COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol 2005; 23: 2840-55.
3. Appleby SB, Ristimaki A, Neilson K, et al. Structure of the human cyclo-oxygenase-2gene. Biochem J 1994; 302: 723-7.
4. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000; 60: 1306-11.
5. Raju R, Cruz-Correa M. Chemoprevention of colorectal cancer. Dis Colon Rectum 2006; 49: 113-25.
6. Steinbach G, Lynch PM, Philips RK, et al. The effect of celecoxib,a cyclooxygenase -2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342: 1946-52.
7. Bisacchi D, Benelli R, Vanzetto C, et al. Anti-angiogenesis and angioprevention mechanisms: problems and perspectives. Cancer Detect Prev 2003; 27: 229-38.
8. Hilmi I, Goh KL. Chemoprevention of colorectal cancer with nonsteroidal anti-inflammatory drugs. Chin J Dig Dis 2006; 7: 1-6.
9. Husain SS, Szabo IL, Tamawski AS. NSAID inhibition of GI cancer growth:clinical implications and molecular mechanisms of action. Am J Gastroenterol 2002; 97: 542-53.
10. Grosch S, Tegeder I, Niederberger E, et al. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 2001; 15: 2742-4.
11. Dannenberg AJ, Lippman SM, Mann JR, et al. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 2005; 23: 254-66.
12. Hawk ET, Levin B. Colorectal cancerprevention. J Clin Oncol 2005; 23: 379-91.
13. Sínicrope FA, Gill S. Role of cyclooxygenase-2 in colorectal cancer. Cancer Metastasis Rev 2004; 23: 63-75.
14. Shoji T, Konno H, Tanaka T, et al. Orthotopic implantation of a colon cancer xenograft induces high expression of cyclooxygenase-2. Cancer Lett 2003; 195: 235-41.
15. Reddy BS, Hirose Y, Lubet R, et al. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor,celecoxib, administered during different stages of carcinogenesis. Cancer Res 2000; 60: 293-7.
16. Sato H, Ishihara S, Kawashima K, et al. Expression of peroxisome proliferator-activated receptor (PPAR) gamma in gastric cancer and inhibitory effects of PPARgamma agonists. Br J Cancer 2000; 83: 1394-400.
17. Fu J, Wang W, Bai X, et al. Coexpression of vascular endothelial growth factor and its receptors in human tumor cell lines. Chinese J of Cancer 2002; 21: 1217-21.
18. Song J, Qian W, Hou X. A Study the mechamisms of apoptosis of gastric cancer line induced by indomethacin. Chinese J of Clin Digest Dis 2003; 15: 249-53.
19. Yan C, Li C, Tian F, et al. Fibronectin induces matrix metalloproteinase-2 expression in ovarian cancer cells. Chin J Oncol 2000; 22: 109-12.
20. Weidner N. Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 1995; 147: 9-19.
21. Fujimura T, Ohta T, Oyama K, et al. Role of cyclooxygenase-2 in the carcinogenesis of gastrointestinal tract cancers: a review and report of personal experience. World J Gastroenterol 2006; 12: 1336-45.
22. Watson AJ. Apoptosis and colorectal cancer. Gut 2004; 53: 1701-9.
23. Sanbom R, Blanke CD. Cyclooxygenase-2 inhibition in colorectal cancer boom or bast? Semin Oncol 2005; 32: 69-75.
24. Kismet K, Akay MT, Abbasoglu O, et al. Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention. Cancer Detect Prev 2004; 28: 127-42.
25. Sheng H, Shao J, Washington MK, et al. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 2001; 276: 18075-81.
26. Shao J, Lee SB, Guo H, et al. Prostaglandin E2 stimulates the growth of colon cancer cells via induction of amphiregulin. Cancer Res 2003; 63: 5218-23.
27. Pai R, Nakamura T, Moon WS, et al. Prostaglandins promote colon cancer cell invasion; signaling by cross-talk between two distinct growth factor receptors. FASEB J 2003; 17: 1640-7.
28. Shao J, Evers BM, Sheng H. Prostaglandin E2 synergistically enhances receptor tyrosine kinase-dependent signaling system in colon cancer cells. Biol Chem 2004; 279: 14287-93.
29. 2 regulates the angiogenic switch. PNAS 2004; 101: 415-6.
30. 2 in human prostatic carcinoma cells. Br J Cancer 1997; 75: 1111-8.
31. Chun KS, Kim SH, Song YS, et al. Celecoxib inhibits phorbol ester-induced expression of COX-2 and activation of AP-1 and p38 MAP kinase in mouse skin. Carcinogenesis 2004; 25: 713-22.
32. Shishodia S, Koul D, Aggarwal BB. Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NFκB activation through inhibition of activation of IκBα kinase and Akt in human non-small cell lung carcinoma: correlation with suppression of COX-2 synthesis. J Immunol 2004; 173: 2011-22.
33. Arico S, Pattingre S, Bauvy C, et al. Celecoxib induces apoptosis by inhibiting 3-phosphoinositidedependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J Biol Chem 2002; 277: 27613-21.
34. Wu T, Leng J, Han C, et al. The cyclooxygenase-2 inhibitor celecoxib blocks phosphorylation of Akt and induces apoptosis in human cholangiocarcinoma cells. Mol Cancer Ther 2004; 3: 299-307.
35. Grosch S, Tegeder I, Niederberger E, et al. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 2001; 15: 2742-4.
36. Shureiqi I, Chen D, Lee JJ, et al. 15-LOX-1: a novel molecular target of nonsteroidal anti-inflammatory drug-induced apoptosis in colorectal cancer cells. J Natl Cancer Inst 2000; 92: 1136-42.
37. Michael MS, Badr MZ, Badawi AF. Inhibition of cyclooxygenase-2 and activation of peroxisome proliferator-activated receptor-γ synergistically induces apoptosis and inhibits growth of human breast cancer cells. Int J Mol Med 2003; 11: 733-6.
38. Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase- independent actions of cyclooxygenase inhibitors. FASEB J 2001; 15: 2057-72.
39. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004; 9: 2-10.
40. 2-dependent angiogenesis in APC (Delta716) mouse intestinal polyps. Cancer Res 2002; 62: 506-11.
41. Zucker S, Vacirca J. Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev 2004; 23: 101-17.
42. Takahashi Y, Kawahara F, Noguchi M, et al. Activation of matrix metalloproteinase-2 in human breast cancer cells overexpressing cyclooxygenase-1 or-2. FEBS Lett 1999; 460: 145-8.
43. Pan MR, Chuang LY, Hung WC. Non-steroidal antiinflammatory drugs inhibit matrix metalloproteinase-2 expression via repression of transcription in lung cancer cells. FEBS Lett 2001; 508: 365-8.
44. Attiga FA, Fernandez PM, Weeraratna AT, et al. Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res 2000; 60: 4629-37.
45. Gasparini G, Longo R, Fanelli M, et al. Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. J Clin Oncol 2005; 23: 1295-311.